The Role of ADRB2 in Myasthenia: Genetic and Immunological Factors

• Published in: Bulletin of experimental biology and medicine Vol. 154; no. 3; pp. 351 - 353
• Main Authors: Lantsova, V. B., Gerasimov, A. S., Sepp, E. K.
• Format: Journal Article
• Language: English
• Published: Boston Springer US 2013; Springer; Springer Nature B.V
• Subjects: Adolescent; Adrenergic Agonists - therapeutic use; Adrenergic receptors; Adult; Antigen-antibody reactions; Autoantibodies; Autoantibodies - blood; Biological products; Biomedical and Life Sciences; Biomedicine; Cell Biology; Child; Enzyme-linked immunosorbent assay; Genetic engineering; Genetic research; Genetically modified organisms; Genetics; Genotype; Glycine; Humans; Internal Medicine; Laboratory Medicine; Middle Aged; Mutation; Myasthenia Gravis - genetics; Myasthenia Gravis - immunology; Pathology; Receptors, Adrenergic, beta-2 - genetics; Receptors, Adrenergic, beta-2 - immunology; Severity of Illness Index; Young Adult; polymorphism; antibodies against; myasthenia; ELISA
• ISSN: 0007-4888; 1573-8221
• DOI: 10.1007/s10517-013-1948-0

To examine the possibility of using ADRB2 adrenergic receptor agonists for correction of myasthenia-induced immunological and motor disturbances, a method of anti-ADRB2 antibody assay by ELISA was developed. The haplotype of ADRB2 gene was determined by MLPA-PCR in 34 myasthenia patients; blood sera from 40 patients were examined. The content of antibodies against ADRB2 receptors was elevated in 12 of 30 patients with generalized form of myasthenia. Arg-Arg in position 16 in ADRB2 receptors determines the developmental risk of side effects, while Gly-Gly in the same codon determines tolerance to β 2 -adrenoceptor agonists and is associated with more severe course of myasthenia and resistance to β 2 -adrenoceptor agonists treatment with ADRB2 agonists. The study demonstrated the possibility of using ADRB2 obtained gene engineering technique for quantitatively assay the autoantibodies.